Proactive research analyst Daniel Appiah speaks to Thomas Warner after publishing a research note on Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP, OTCQB:OCTHF), entitled "Phase 1 approval for lead chronic pain drug."
CEO Clarissa Sowemimo-Coker recently told Proactive's Stephen Gunnion that Medicines and Healthcare products Regulatory Agency (MHRA) approval of a phase 1 trial for its lead pain relief drug candidate, OCT461201, represents a significant milestone for the company.